IL13 and atherosclerosis: Dupilumab is a fully human monoclonal antibody that has been shown to reduce and downregulate pro-inflammatory cytokines such as IL-4 and IL-13, which are key mediators in AD and also involved in the pathogenesis of cardiovascular diseases and atherosclerosis [15,16].